Trials / Suspended
SuspendedNCT00541333
Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration
- Status
- Suspended
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- The New York Eye & Ear Infirmary · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the project is to investigate in eyes with dry AMD, the efficacy and safety as preventive therapy of the immunomodulatory substance named copaxone which had been proven as safe and effective agent for a neurodegenerative disease, in arresting the progression as well as the conversion of dry AMD to wet AMD. The hypothesis that the immunomodulatory agent copaxone proven for a neurodegenerative disease may work in the eye is revolutionary and may open a new avenue of preventive treatment for the disease which is the major cause of legal blindness in the industrial world
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Copaxone Injection |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2012-12-01
- First posted
- 2007-10-10
- Last updated
- 2013-05-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00541333. Inclusion in this directory is not an endorsement.